On January 20, 2022 IntegraGen and BIOASTER reported they have been collaborating for several years in the context of genomic and transcriptomic analyses (Press release, Integragen, JAN 20, 2022, View Source [SID1234605609]). Driven by a desire to strengthen this relationship further, the two entities have entered into a long-term partnership agreement (Master Research Service Agreement). This agreement will facilitate and accelerate exchanges between the two teams, and thus offer integrated, streamlined and efficient solutions aimed at healthcare industries in France.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Created in 2012 from an initiative by the French Technological Research Institute (IRT), BIOASTER is a non-profit foundation with a unique and innovative technological model to meet new challenges related to microbiology and infectious diseases. Its objective is to connect academia and businesses in order to develop and carry out collaborative research projects which have a high impact on patients.
In pursuit of its objectives, BIOASTER seeks to rely on its reference partners, who are leaders in their field. As such, the IRT is able to provide an integrated technological offer adapted to the needs of its research projects, both in terms of variety and volume.
"IntegraGen has demonstrated its ability to respond quickly to our sequencing needs and to provide us with quality data in a timely manner. Here at BIOASTER, we are delighted to strengthen our collaboration with an expert team in whom we have total confidence," says Adrien Saliou, B.Eng, PhD, Genomics and Transcriptomics Team Leader, OMICS Hub, BIOASTER.
"Our collaboration with BIOASTER is based on the responsiveness, communication and professionalism of the teams at both our institutions. It is an honour for IntegraGen to be asked to contribute to the challenge of understanding the mechanisms of biological systems and the fight against infectious agents while working alongside a key player in the field of microbiology," Emmanuel Martin, Chief Operating Officer of the OncoDNA Group.